Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...

Novartis and Apellis Pharmaceuticals have rolled out detailed data on iptacopan and pegcetacoplan, respectively, as they race ...

Shares of Apellis Pharmaceuticals ( APLS 2.47%) are down by about 62% from the peak they reached in January. However, investment bank analysts who follow the drugmaker think its best days are still ...

Empaveli (systemic pegcetacoplan) for paroxysmal nocturnal hemoglobinuria and Syfovre (intravitreal pegcetacoplan) for geographic atrophy secondary to age-related macular degeneration. William ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per ...

SYFOVRE, or any of its future products will warrant regulatory submissions to the FDA or equivalent foreign regulatory agencies; whether systemic pegcetacoplan will receive approval from the FDA ...

SYFOVRE commercial vials grew by approximately ... in early 2025 seeking approval of pegcetacoplan in C3G and IC-MPGN. The FDA did not require Apellis to wait to file with the full 52-week data.

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product sales Grew SYFOVRE® (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product ...